NEWLY DIAGNOSED
If you have been NEWLY DIAGNOSED START HERE
VIDEO LIBRARIES
GRACE is excited to bring to you more in our new series on surviving with cancer GRACE is excited to bring to you more in our series on surviving with...
GRACE is excited to bring to you more in our new series on surviving with cancer GRACE is excited to bring to you more in our series on surviving with...
GRACE is excited to bring to you more in our new series on surviving with cancer GRACE is excited to bring to you more in our series on surviving with...
GRACE is excited to bring to you more in our new series on surviving with cancer GRACE is excited to bring to you more in our series on surviving with...
We are excited to be able to share the following article provided by a member of the GRACE Fellows Ambassador Program, Dr. Arjun Gupta. The article...
ARTICLES
To many, the recent FDA approval of a combination of chemotherapy and concurrent immunotherapy for the vast majority of patients with advanced (metastatic) non-squamous non-small cell lung cancer (NSCLC) probably seems like a great idea.
Dr. Jonathan Goldman joins GRACE to explain why carboplatin, pemetrexed and pembrolizumab has become his new go-to regimen for first-line non-squamous NSCLC treatment.
Over the next few days, about 30,000 oncologists and other cancer care professionals, along with a growing number of patient advocates, are converging...
Over the next few days, about 30,000 oncologists and other cancer care professionals, along with a growing number of patient advocates, are converging...
The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The...
COMMUNITY FORUM
On Saturday, November 10, 2018, GRACE partnered with Swedish Cancer Institute to present a live and webcast discussion on Local Therapies for...
Hi All - I was approached by a WhatNext Group partnered with Rare Patient Voice, with the opportunity to participate in a study specifically for Non...